Royalty Pharma (RPRX) Stock Forecast & Price Target

Royalty Pharma
Bull Case

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

• The stock is trading at $63.11, which is near its 52-week high of $63.29, indicating strong recent momentum and a significant increase from its 52-week low of $34.08, suggesting a robust upward trend in market valuation.
• Wall Street analysts maintain a consensus "Buy" rating with an average price target of $60.86, and recent reports from firms like Goldman Sachs and Citigroup have raised price targets to $66.00, reflecting high confidence in the company's future earnings potential.
• The company recently reported earnings per share of $1.32 for the quarter, which exceeded analyst estimates of $1.27, demonstrating strong profitability with a net margin of 32.14% and a return on equity of 30.01%.
• Short interest has decreased significantly, with the short percentage of float dropping to approximately 2.49% as of August 2026, indicating that fewer investors are betting against the stock and reducing the risk of a short squeeze.
• Institutional investors are increasing their holdings, with new investments from entities like the Public Employees Retirement System of Ohio and Morgan Stanley lifting its stake by 25.2%, signaling strong institutional confidence in the company's long-term stability.